Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Atherosclerosis Reports
Erschienen in: Current Atherosclerosis Reports 1/2013

01.01.2013 | Nonstatin Drugs (WB Borden, Section Editor)

Lipid Effects of Psychiatric Medications

verfasst von: Junzo Watanabe, Yutaro Suzuki, Toshiyuki Someya

Erschienen in: Current Atherosclerosis Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

People with schizophrenia have higher rates of medical illness and mortality than the general population. Cardiovascular disease is a major contributor to premature death in patients with schizophrenia. There has been an increase literature discussing the high prevalence of dyslipidemia, which is one of risk factors for cardiovascular disease, induced by second generation antipsychotic agents. Depression is associated with increased risks of diabetes, hypertension, cardiovascular disease. However, those may not be secondary to the use of antidepressant agents. In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. Further investigations are needed to evaluate the effects of antidepressive agents on lipid profiles.
Literatur
1.
Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatr Suppl. 2004;47:S102–5.CrossRef
2.
Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol. 2005;19:47–55.PubMedCrossRef
3.
McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
4.
Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.PubMedCrossRef
5.
Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66:848–56.
6.
Viron MJ, Stern TA. The impact of serious mental illness on health and healthcare. Psychosomatics. 2010;51:458–65.PubMed
7.
Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatr. 1991;36:239–45.
8.
Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115–21.PubMedCrossRef
9.
Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45:21–8.PubMedCrossRef
10.
Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci. 2002;71:239–57.PubMedCrossRef
11.
Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatr. 2004;65:715–20.CrossRef
12.
Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.
13.
George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835–42.PubMedCrossRef
14.
Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatr Res. 2001;101:277–88.CrossRef
15.
Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–96.PubMed
16.
Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatr. 1999;60:215–20.CrossRef
17.
Czobor P, Volavka J, Sheitman B, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol. 2002;22:244–51.PubMedCrossRef
18.
Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatr. 2001;62 Suppl 27:27–34. discussion 40–21.
19.
Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care. 2003;26:1597–605.PubMedCrossRef
20.
Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697–701.PubMedCrossRef
21.
Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatr. 1996;37:68–73.CrossRef
22.
Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses—a comparison between different antipsychotic agents. Psychopharmacology (Berl). 2001;154:205–12.CrossRef
23.
Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;157:975–81.PubMedCrossRef
24.
Pan A, Lucas M, Sun Q, et al. Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med. 2010;170:1884–91.PubMedCrossRef
25.
Patten SB, Williams JV, Lavorato DH, et al. Major depression as a risk factor for high blood pressure: epidemiologic evidence from a national longitudinal study. Psychosom Med. 2009;71:273–9.PubMedCrossRef
26.
Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.PubMedCrossRef
27.
• Pan A, Sun Q, Okereke OI, et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011;306:1241–9. They described the relationship between depressive disorder and cardiovascular disease.PubMedCrossRef
28.
Salaycik KJ, Kelly-Hayes M, Beiser A, et al. Depressive symptoms and risk of stroke: the Framingham Study. Stroke. 2007;38:16–21.PubMedCrossRef
29.
Shimbo D, Chaplin W, Crossman D, et al. Role of depression and inflammation in incident coronary heart disease events. Am J Cardiol. 2005;96:1016–21.PubMedCrossRef
30.
Strine TW, Mokdad AH, Dube SR, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatr. 2008;30:127–37.CrossRef
31.
• Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220–9. They described the relationship between depressive disorder and cardiovascular disease.PubMedCrossRef
32.
Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91:465–71.PubMedCrossRef
33.
•• Liao CH, Chang CS, Wei WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011;126:110–6. It investigated the risks of developing diabetes mellitus, hypertension, and hyperlipidemia in treating schizophrenia with first and second generation antipsychotics. The effect of antipsychotic agents on lipid metabolism is a serious concern in psychiatric medication and their study is important.
34.
Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatr. 2002;63:425–33.CrossRef
35.
Patel JK, Buckley PF, Woolson S, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009;111:9–16.PubMedCrossRef
36.
Duncan EJ, Woolson SL, Hamer RM, et al. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol. 2009;24:204–13.PubMedCrossRef
37.
Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–31.PubMedCrossRef
38.
Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm. 1996;53:2079–81.PubMed
39.
Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168:947–56.PubMedCrossRef
40.
Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596–601.
41.
Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatr. 2004;49:753–60.
42.
McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19–32.PubMedCrossRef
43.
Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007;191:23–9.PubMedCrossRef
44.
Watanabe J, Suzuki Y, Sugai T, et al. The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents. Gen Hosp Psychiatr. 2012;34:525–8.CrossRef
45.
Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–26.PubMedCrossRef
46.
de Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007;92:95–102.PubMedCrossRef
47.
Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28:132–7.PubMedCrossRef
48.
McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802–9.PubMed
49.
Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov. 2005;4:193–205.PubMedCrossRef
50.
51.
Domon SE, Webber JC. Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacol. 2001;11:285–8.PubMedCrossRef
52.
Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatr. 2002;41:495–6.CrossRef
53.
Nguyen M, Murphy T. Olanzapine and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatr. 2001;40:133.CrossRef
54.
Wetterling T. Hyperlipidemia--side-effect of the treatment with an atypical antipsychotic (zotepine)? Psychiatr Prax. 2002;29:438–40.PubMedCrossRef
55.
Jerrell JM, Tripathi A, Rizvi AA et al. The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis. Prim Care Companion CNS Disord 2012, 14.
56.
• Pyykkonen AJ, Raikkonen K, Tuomi T, et al. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: results from the PPP-Botnia Study. Ann Med. 2012;44:279–88. The relationship between depressive disorder and cardiovascular disease may not be driven by the use of antidepressive agents.
Metadaten
Titel
Lipid Effects of Psychiatric Medications
verfasst von
Junzo Watanabe
Yutaro Suzuki
Toshiyuki Someya
Publikationsdatum
01.01.2013
Verlag
Current Science Inc.
Erschienen in
Current Atherosclerosis Reports / Ausgabe 1/2013
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0292-6

Weitere Artikel der Ausgabe 1/2013

Current Atherosclerosis Reports 1/2013 Zur Ausgabe

Statin Drugs (MB Clearfield, Section Editor)

The Rationale for Initiating Treatment of Hypercholesterolemia in Young Adulthood

Statin Drugs (MB Clearfield, Section Editor)

Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?

Nonstatin Drugs (WB Borden, Section Editor)

Vitamin D, Calcium, and Atherosclerotic Risk: Evidence from Serum Levels and Supplementation Studies

Statin Drugs (MB Clearfield, Section Editor)

Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?

Statin Drugs (MB Clearfield, Section Editor)

How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy?

Statin Drugs (MB Clearfield, Section Editor)

Is Atherosclerosis Regression a Realistic Goal of Statin Therapy and What Does That Mean?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise